The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sharma, S.
Right arrow Articles by Dubinett, S. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sharma, S.
Right arrow Articles by Dubinett, S. M.
The Journal of Immunology, 2005, 175: 813-819.
Copyright © 2005 by The American Association of Immunologists

Cyclooxygenase 2 Inhibition Promotes IFN-{gamma}-Dependent Enhancement of Antitumor Responses1

Sherven Sharma*,{dagger},{ddagger}, Li Zhu*,{ddagger}, Seok Chul Yang*, Ling Zhang*, Jeff Lin*,{ddagger}, Sven Hillinger*, Brian Gardner{ddagger}, Karen Reckamp*, Robert M. Strieter*,{dagger}, Min Huang*,{ddagger}, Raj K. Batra*,{dagger},{ddagger} and Steven M. Dubinett2,*,{dagger},{ddagger}

* Department of Medicine, Lung Cancer Research Program, and{dagger} Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, CA 90095-1690; and{ddagger} Molecular Gene Medicine Laboratory, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA 90073

In previous studies, we demonstrated an immune suppressive network in non-small cell lung cancer that is due to overexpression of tumor cyclooxygenase 2 (COX-2). In this study, we assessed the vaccination response to tumor challenge following either pharmacological or genetic inhibition of COX-2 in a murine lung cancer model. Treatment of naive mice with the COX-2 inhibitor, SC-58236, skewed splenocytes toward a type 1 cytokine response, inducing IFN-{gamma}, IL-12, and IFN-{gamma}-inducible protein 10, whereas the type 2 cytokines IL-4, IL-5, and IL-10 remained unaltered. Fifty percent of mice receiving SC-58236 and an irradiated tumor cell vaccine completely rejected tumors upon challenge. Those mice that did form tumors following challenge demonstrated a reduced tumor growth. In contrast, all mice either vaccinated with irradiated tumor cells alone or receiving SC-58236 alone showed progressive tumor growth. Studies performed in CD4 and CD8 knockout mice revealed a requirement for the CD4 T lymphocyte subset for the complete rejection of tumors. To determine the role of host COX-2 expression on the vaccination responses, studies were performed in COX-2 gene knockout mice. Compared with control littermates, COX-2–/– mice showed a significant tumor growth reduction, whereas heterozygous COX-2–/+ mice had an intermediate tumor growth reduction following vaccination. In vivo depletion of IFN-{gamma} abrogated the COX-2 inhibitor-mediated enhancement of the vaccination effect. These findings provide a strong rationale for additional evaluation of the capacity of COX-2 inhibitors to enhance vaccination responses against cancer.




This article has been cited by other articles:


Home page
J. Immunol.Home page
E. Eruslanov, S. Kaliberov, I. Daurkin, L. Kaliberova, D. Buchsbaum, J. Vieweg, and S. Kusmartsev
Altered Expression of 15-Hydroxyprostaglandin Dehydrogenase in Tumor-Infiltrated CD11b Myeloid Cells: A Mechanism for Immune Evasion in Cancer
J. Immunol., June 15, 2009; 182(12): 7548 - 7557.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. E. Talmadge
Pathways Mediating the Expansion and Immunosuppressive Activity of Myeloid-Derived Suppressor Cells and Their Relevance to Cancer Therapy
Clin. Cancer Res., September 15, 2007; 13(18): 5243 - 5248.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
P. Sinha, V. K. Clements, A. M. Fulton, and S. Ostrand-Rosenberg
Prostaglandin E2 Promotes Tumor Progression by Inducing Myeloid-Derived Suppressor Cells
Cancer Res., May 1, 2007; 67(9): 4507 - 4513.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
E. P. Ryan, C. M. Malboeuf, M. Bernard, R. C. Rose, and R. P. Phipps
Cyclooxygenase-2 Inhibition Attenuates Antibody Responses against Human Papillomavirus-Like Particles
J. Immunol., December 1, 2006; 177(11): 7811 - 7819.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Dohadwala, S.-C. Yang, J. Luo, S. Sharma, R. K. Batra, M. Huang, Y. Lin, L. Goodglick, K. Krysan, M. C. Fishbein, et al.
Cyclooxygenase-2-Dependent Regulation of E-Cadherin: Prostaglandin E2 Induces Transcriptional Repressors ZEB1 and Snail in Non-Small Cell Lung Cancer.
Cancer Res., May 15, 2006; 66(10): 5338 - 5345.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. R. Haas, J. Sun, A. Vachani, A. F. Wallace, M. Silverberg, V. Kapoor, and S. M. Albelda
Cycloxygenase-2 Inhibition Augments the Efficacy of a Cancer Vaccine
Clin. Cancer Res., January 1, 2006; 12(1): 214 - 222.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.